CAR-T Long Term Follow Up (LTFU) study

Phase 1

Recruiting

• Conditions: All patients who have been treated with Novartis or Penn CAR-T for any indication; MedDRA version: 21.0Level: PTClassification code: 10003917Term: B-cell type acute leukaemia Class: 100000004864; MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104; MedDRA version: 20.0Level: PTClassification code: 10003899Term: B-cell lymphoma Class: 100000004864; Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: CTIS2023-508128-37-00
• Lead Sponsor: ovartis Pharma Services AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-15
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1119

Inclusion Criteria

Patients must have received CAR-T therapy within one of the following: •Novartis or Penn sponsored CAR-T treatment trials where CAR-T was given as monotherapy or as combination therapy. •Novartis managed access programs (MAP) outside of the commercial setting, i.e. where CAR-T therapy was intended to be given in the setting of a Novartis or Penn sponsored CAR-T treatment trial, Patients must provide informed consent prior to their entry into this study

Exclusion Criteria

There are no specific exclusion criteria for this study.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified